Volume 22: Issue 2 (Aug 2023): End-Stage Kidney Disease

KDOQI; National Kidney Foundation: KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47[Suppl 3]: S11–S145, 2006 PubMed

• PubMed
KDOQI; National Kidney Foundation: KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47[Suppl 3]: S11–S145, 2006 PubMed)| false
• Search Google Scholar
• Export Citation

Kovesdy CP, Davis JR, Duling I, Little DJ: Prevalence of anaemia in adults with chronic kidney disease in a representative sample of the United States population: Analysis of the 1999-2018 National Health and Nutrition Examination Survey. Clin Kidney J 16: 303–311, 2022 PubMed

• PubMed
Kovesdy CP, Davis JR, Duling I, Little DJ: Prevalence of anaemia in adults with chronic kidney disease in a representative sample of the United States population: Analysis of the 1999-2018 National Health and Nutrition Examination Survey. Clin Kidney J 16: 303–311, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Farrington DK, Sang Y, Grams ME, Ballew SH, Dunning S, Stempniewicz N, et al.: Anemia prevalence, type, and associated risks in a cohort of 5.0 million insured patients in the United States by level of kidney function. Am J Kidney Dis 81: 201–209.e1, 2023 PubMed

• PubMed
Farrington DK, Sang Y, Grams ME, Ballew SH, Dunning S, Stempniewicz N, et al.: Anemia prevalence, type, and associated risks in a cohort of 5.0 million insured patients in the United States by level of kidney function. Am J Kidney Dis 81: 201–209.e1, 2023 PubMed)| false
• Search Google Scholar
• Export Citation

Minutolo R, Grandaliano G, Di Rienzo P, Snijder R, Degli Esposti L, Perrone V, et al.: Prevalence, incidence, and treatment of anaemia in patients with non-dialysis-dependent chronic kidney disease: Findings from a retrospective real-world study in Italy. J Nephrol 36: 347–357, 2023 PubMed

• PubMed
Minutolo R, Grandaliano G, Di Rienzo P, Snijder R, Degli Esposti L, Perrone V, et al.: Prevalence, incidence, and treatment of anaemia in patients with non-dialysis-dependent chronic kidney disease: Findings from a retrospective real-world study in Italy. J Nephrol 36: 347–357, 2023 PubMed)| false
• Search Google Scholar
• Export Citation

Lopes MB, Tu C, Zee J, Guedes M, Pisoni RL, Robinson BM, et al.: A real-world longitudinal study of anemia management in non-dialysis-dependent chronic kidney disease patients: A multinational analysis of CKDopps. Sci Rep 11: 1784, 2021 10.1038/s41598-020-79254-6 PubMed

• PubMed
Lopes MB, Tu C, Zee J, Guedes M, Pisoni RL, Robinson BM, et al.: A real-world longitudinal study of anemia management in non-dialysis-dependent chronic kidney disease patients: A multinational analysis of CKDopps. Sci Rep 11: 1784, 2021 10.1038/s41598-020-79254-6 PubMed)| false
• Search Google Scholar
• Export Citation

Zaoui P, Courivaud C, Rostoker G, Choukroun G, Dubel L, Lorenzo M, et al.: Management of anaemia in French dialysis patients: Results from a large epidemiological retrospective study. Clin Kidney J 16: 501–511, 2022 10.1093/ckj/sfac245 PubMed

• PubMed
Zaoui P, Courivaud C, Rostoker G, Choukroun G, Dubel L, Lorenzo M, et al.: Management of anaemia in French dialysis patients: Results from a large epidemiological retrospective study. Clin Kidney J 16: 501–511, 2022 10.1093/ckj/sfac245 PubMed)| false
• Search Google Scholar
• Export Citation

Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, et al.: PIVOTAL investigators and committees. N Engl J Med 380: 447-458, 2019.

• PubMed
Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, et al.: PIVOTAL investigators and committees. N Engl J Med 380: 447-458, 2019.)| false
• Search Google Scholar
• Export Citation

Bernhardt WM, Wiesener MS, Scigalla P, Chou J, Schmieder RE, Günzler V, et al.: Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 21: 2151–2156, 2010 PubMed

• PubMed
Bernhardt WM, Wiesener MS, Scigalla P, Chou J, Schmieder RE, Günzler V, et al.: Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 21: 2151–2156, 2010 PubMed)| false
• Search Google Scholar
• Export Citation

Wang GL, Jiang BH, Rue EA, Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 92: 5510–5514, 1995 PubMed

• PubMed
Wang GL, Jiang BH, Rue EA, Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 92: 5510–5514, 1995 PubMed)| false
• Search Google Scholar
• Export Citation

Babitt JL, Eisenga MF, Haase VH, Kshirsagar AV, Levin A, Locatelli F, et al; Conference Participants: Controversies in optimal anemia management: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney Int 99: 1280–1295, 2021 PubMed

• PubMed
Babitt JL, Eisenga MF, Haase VH, Kshirsagar AV, Levin A, Locatelli F, et al; Conference Participants: Controversies in optimal anemia management: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney Int 99: 1280–1295, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Batchelor EK, Kapitsinou P, Pergola PE, Kovesdy C, Jalal DI. Iron deficiency in chronic kidney disease: Updates on pathophysiology, diagnosis and treatment. J Am Soc Nephrol 31: 456, 2020.

• PubMed
Batchelor EK, Kapitsinou P, Pergola PE, Kovesdy C, Jalal DI. Iron deficiency in chronic kidney disease: Updates on pathophysiology, diagnosis and treatment. J Am Soc Nephrol 31: 456, 2020.)| false
• Search Google Scholar
• Export Citation

Agarwal AK: Practical approach to the diagnosis and treatment of anemia associated with CKD in elderly. J Am Med Dir Assoc 7[Suppl]: S7–S12, quiz S17–S21, 2006 PubMed

• PubMed
Agarwal AK: Practical approach to the diagnosis and treatment of anemia associated with CKD in elderly. J Am Med Dir Assoc 7[Suppl]: S7–S12, quiz S17–S21, 2006 PubMed)| false
• Search Google Scholar
• Export Citation

Honda H, Kobayashi Y, Onuma S, Shibagaki K, Yuza T, Hirao K, et al.: Associations among erythroferrone and biomarkers of erythropoiesis and iron metabolism, and treatment with long-term erythropoiesis-stimulating agents in patients on hemodialysis. PLoS One 11: e0151601, 2016 10.1371/journal.pone.0151601 PubMed

• PubMed
Honda H, Kobayashi Y, Onuma S, Shibagaki K, Yuza T, Hirao K, et al.: Associations among erythroferrone and biomarkers of erythropoiesis and iron metabolism, and treatment with long-term erythropoiesis-stimulating agents in patients on hemodialysis. PLoS One 11: e0151601, 2016 10.1371/journal.pone.0151601 PubMed)| false
• Search Google Scholar
• Export Citation

Hanudel MR, Rappaport M, Chua K, Gabayan V, Qiao B, Jung G, et al.: Levels of the erythropoietin-responsive hormone erythroferrone in mice and humans with chronic kidney disease. Haematologica 103: e141–e142, 2018 10.3324/haematol.2017.181743 PubMed

• PubMed
Hanudel MR, Rappaport M, Chua K, Gabayan V, Qiao B, Jung G, et al.: Levels of the erythropoietin-responsive hormone erythroferrone in mice and humans with chronic kidney disease. Haematologica 103: e141–e142, 2018 10.3324/haematol.2017.181743 PubMed)| false
• Search Google Scholar
• Export Citation

Spoto B, Kakkar R, Lo L, Devalaraja M, Pizzini P, Torino C, et al.: Serum erythroferrone levels associate with mortality and cardiovascular events in hemodialysis and CKD patients: A two cohort study. J Clin Med 8: 523, 2019 10.3390/jcm8040523 PubMed

• PubMed
Spoto B, Kakkar R, Lo L, Devalaraja M, Pizzini P, Torino C, et al.: Serum erythroferrone levels associate with mortality and cardiovascular events in hemodialysis and CKD patients: A two cohort study. J Clin Med 8: 523, 2019 10.3390/jcm8040523 PubMed)| false
• Search Google Scholar
• Export Citation

Hanudel MR, Eisenga MF, Rappaport M, Chua K, Qiao B, Jung G, et al.: Effects of erythropoietin on fibroblast growth factor 23 in mice and humans. Nephrol Dial Transplant 34: 2057–2065, 2019. PubMed

• PubMed
Hanudel MR, Eisenga MF, Rappaport M, Chua K, Qiao B, Jung G, et al.: Effects of erythropoietin on fibroblast growth factor 23 in mice and humans. Nephrol Dial Transplant 34: 2057–2065, 2019. PubMed)| false
• Search Google Scholar
• Export Citation

David V, Martin A, Isakova T, Spaulding C, Qi L, Ramirez V, et al.: Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int 89: 135–146, 2016 PubMed

• PubMed
David V, Martin A, Isakova T, Spaulding C, Qi L, Ramirez V, et al.: Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int 89: 135–146, 2016 PubMed)| false
• Search Google Scholar
• Export Citation

David V, Francis C, Babitt JL: Ironing out the cross talk between FGF23 and inflammation. Am J Physiol Renal Physiol 312: F1–F8, 2017 PubMed

• PubMed
David V, Francis C, Babitt JL: Ironing out the cross talk between FGF23 and inflammation. Am J Physiol Renal Physiol 312: F1–F8, 2017 PubMed)| false
• Search Google Scholar
• Export Citation

Singh S, Grabner A, Yanucil C, Schramm K, Czaya B, Krick S, et al.: Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int 90: 985–996, 2016 PubMed

• PubMed
Singh S, Grabner A, Yanucil C, Schramm K, Czaya B, Krick S, et al.: Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int 90: 985–996, 2016 PubMed)| false
• Search Google Scholar
• Export Citation

Goyer RA, Rhyne BC: Pathological effects of lead. Int Rev Exp Pathol 12: 1–77, 1973 PubMed

• PubMed
Goyer RA, Rhyne BC: Pathological effects of lead. Int Rev Exp Pathol 12: 1–77, 1973 PubMed)| false
• Search Google Scholar
• Export Citation

Turgut S, Polat A, Inan M, Turgut G, Emmungil G, Bican M, et al.: Interaction between anemia and blood levels of iron, zinc, copper, cadmium and lead in children. Indian J Pediatr 74: 827–830, 2007 PubMed

• PubMed
Turgut S, Polat A, Inan M, Turgut G, Emmungil G, Bican M, et al.: Interaction between anemia and blood levels of iron, zinc, copper, cadmium and lead in children. Indian J Pediatr 74: 827–830, 2007 PubMed)| false
• Search Google Scholar
• Export Citation

Recasens V, Montañés A, Bustamante E: Lead poisoning as final diagnosis in a study of normocytic anemia. Int J Hematol 109: 135–136, 2019 PubMed

• PubMed
Recasens V, Montañés A, Bustamante E: Lead poisoning as final diagnosis in a study of normocytic anemia. Int J Hematol 109: 135–136, 2019 PubMed)| false
• Search Google Scholar
• Export Citation

Blake KCH, Mann M: Effect of calcium and phosphorus on the gastrointestinal absorption of 203Pb in man. Environ Res 30: 188–194, 1983 PubMed

• PubMed
Blake KCH, Mann M: Effect of calcium and phosphorus on the gastrointestinal absorption of 203Pb in man. Environ Res 30: 188–194, 1983 PubMed)| false
• Search Google Scholar
• Export Citation

Barton JC, Conrad ME, Nuby S, Harrison L: Effects of iron on the absorption and retention of lead. J Lab Clin Med 92: 536–547, 1978 PubMed

• PubMed
Barton JC, Conrad ME, Nuby S, Harrison L: Effects of iron on the absorption and retention of lead. J Lab Clin Med 92: 536–547, 1978 PubMed)| false
• Search Google Scholar
• Export Citation

Subha Palaneeswar M, Rajan PM, Santhi S, Jothimalar: Blood lead in end-stage renal disease (ESRD) patients who were on maintainence haemodialysis. J Clin Diagn Res 6: 1633–1635, 2012 PubMed

• PubMed
Subha Palaneeswar M, Rajan PM, Santhi S, Jothimalar: Blood lead in end-stage renal disease (ESRD) patients who were on maintainence haemodialysis. J Clin Diagn Res 6: 1633–1635, 2012 PubMed)| false
• Search Google Scholar
• Export Citation

Danziger J, Mukamal KJ, Weinhandl E: Associations of community water lead concentrations with hemoglobin concentrations and erythropoietin-stimulating agent use among patients with advanced CKD. J Am Soc Nephrol 32: 2425–2434, 2021 PubMed

• PubMed
Danziger J, Mukamal KJ, Weinhandl E: Associations of community water lead concentrations with hemoglobin concentrations and erythropoietin-stimulating agent use among patients with advanced CKD. J Am Soc Nephrol 32: 2425–2434, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Danziger J, Mukamal KJ: Levels of lead in residential drinking water and iron deficiency among patients with end stage kidney disease. Kidney360 3: 1210–1216, 2022 PubMed

• PubMed
Danziger J, Mukamal KJ: Levels of lead in residential drinking water and iron deficiency among patients with end stage kidney disease. Kidney360 3: 1210–1216, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Nigra A, Navas-Acien A: Racial inequalities in drinking water lead exposure: A wake-up call to protect patients with end stage kidney disease. J Am Soc Nephrol 32: 2419-2421, 2021.

• PubMed
Nigra A, Navas-Acien A: Racial inequalities in drinking water lead exposure: A wake-up call to protect patients with end stage kidney disease. J Am Soc Nephrol 32: 2419-2421, 2021.)| false
• Search Google Scholar
• Export Citation

Shah YM, Xie L: Hypoxia-inducible factors link iron homeostasis and erythropoiesis. Gastroenterology 146: 630–642, 2014 PubMed

• PubMed
Shah YM, Xie L: Hypoxia-inducible factors link iron homeostasis and erythropoiesis. Gastroenterology 146: 630–642, 2014 PubMed)| false
• Search Google Scholar
• Export Citation

Kushida N, Nomura S, Mimura I, Fujita T, Yamamoto S, Nangaku M, et al.: Hypoxia-inducible factor-1α activates the transforming growth factor-β/SMAD3 pathway in kidney tubular epithelial cells Am J Nephrol 44: 276–285, 2016 PubMed

• PubMed
Kushida N, Nomura S, Mimura I, Fujita T, Yamamoto S, Nangaku M, et al.: Hypoxia-inducible factor-1α activates the transforming growth factor-β/SMAD3 pathway in kidney tubular epithelial cells Am J Nephrol 44: 276–285, 2016 PubMed)| false
• Search Google Scholar
• Export Citation

Fishbane S, El-Shahawy MA, Pecoits-Filho R, Pham Van B, Houser MT, Frison L, et al.: Roxadustat for treating anemia in patients with CKD not on dialysis: Results from a randomized phase 3 study. J Am Soc Nephrol 32: 737–755, 2021.

• PubMed
Fishbane S, El-Shahawy MA, Pecoits-Filho R, Pham Van B, Houser MT, Frison L, et al.: Roxadustat for treating anemia in patients with CKD not on dialysis: Results from a randomized phase 3 study. J Am Soc Nephrol 32: 737–755, 2021.)| false
• Search Google Scholar
• Export Citation

Provenzano R, Szczech L, Leong R, Saikali KG, Zhong M, Lee TT, et al.: Efficacy and cardiovascular safety of roxadustat for treatment of anemia in patients with non-dialysis-dependent CKD: Pooled results of three randomized clinical trials. Clin J Am Soc Nephrol 16: 1190–1200, 2021.

• PubMed
Provenzano R, Szczech L, Leong R, Saikali KG, Zhong M, Lee TT, et al.: Efficacy and cardiovascular safety of roxadustat for treatment of anemia in patients with non-dialysis-dependent CKD: Pooled results of three randomized clinical trials. Clin J Am Soc Nephrol 16: 1190–1200, 2021.)| false
• Search Google Scholar
• Export Citation

Shutov E, Sulowicz W, Esposito C, Tataradze A, Andric B, Reusch M, et al.: Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: A Phase 3, randomized, double-blind, placebo-controlled study (ALPS). Nephrol Dial Transplant 36: 1629–1639, 2021.

• PubMed
Shutov E, Sulowicz W, Esposito C, Tataradze A, Andric B, Reusch M, et al.: Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: A Phase 3, randomized, double-blind, placebo-controlled study (ALPS). Nephrol Dial Transplant 36: 1629–1639, 2021.)| false
• Search Google Scholar
• Export Citation

Coyne DW, Roger SD, Shin SK, Kim SG, Cadena AA, Moustafa MA, et al.: Roxadustat for CKD-related anemia in non-dialysis patients. Kidney Int Rep 6: 624-635, 2020.

• PubMed
Coyne DW, Roger SD, Shin SK, Kim SG, Cadena AA, Moustafa MA, et al.: Roxadustat for CKD-related anemia in non-dialysis patients. Kidney Int Rep 6: 624-635, 2020.)| false
• Search Google Scholar
• Export Citation

Singh AJ, Cizman B, Carroll K, McMurray JJV, Perkovic V, Vivekanand J, et al.: Efficacy and safety of daprodustat for treatment of anemia of chronic kidney disease in incident dialysis patients: A randomized clinical trial. JAMA Intern Med 182: 592–602, 2022.

• PubMed
Singh AJ, Cizman B, Carroll K, McMurray JJV, Perkovic V, Vivekanand J, et al.: Efficacy and safety of daprodustat for treatment of anemia of chronic kidney disease in incident dialysis patients: A randomized clinical trial. JAMA Intern Med 182: 592–602, 2022.)| false
• Search Google Scholar
• Export Citation

Coyne DW, Singh AK, Lopes RD, Bailey CK, DiMino TL, Huang C, et al.: Three times weekly dosing of daprodustat versus conventional epoetin for treatment of anemia in hemodialysis patients: ASCEND-TD: A phase 3 randomized, double-blind, noninferiority trial. Clin J Am Soc Nephrol 17: 1325–1336, 2022.

• PubMed
Coyne DW, Singh AK, Lopes RD, Bailey CK, DiMino TL, Huang C, et al.: Three times weekly dosing of daprodustat versus conventional epoetin for treatment of anemia in hemodialysis patients: ASCEND-TD: A phase 3 randomized, double-blind, noninferiority trial. Clin J Am Soc Nephrol 17: 1325–1336, 2022.)| false
• Search Google Scholar
• Export Citation

Winkelmayer WC, Walther CP: Cardiovascular safety of roxadustat in CKD anemia: A fig leaf named noninferiority. Clin J Am Soc Nephrol 16: 1155–1157, 2021 PubMed

• PubMed
Winkelmayer WC, Walther CP: Cardiovascular safety of roxadustat in CKD anemia: A fig leaf named noninferiority. Clin J Am Soc Nephrol 16: 1155–1157, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Takkavatakarn K, Thammathiwat T, Phannajit J, Katavetin P, Praditpornsilpa K, Eiam-Ong S, et al.: The impacts of hypoxia-inducible factor stabilizers on laboratory parameters and clinical outcomes in chronic kidney disease patients with renal anemia: A systematic review and meta-analysis. Clin Kidney J 16: 845–858, 2023 PubMed

• PubMed
Takkavatakarn K, Thammathiwat T, Phannajit J, Katavetin P, Praditpornsilpa K, Eiam-Ong S, et al.: The impacts of hypoxia-inducible factor stabilizers on laboratory parameters and clinical outcomes in chronic kidney disease patients with renal anemia: A systematic review and meta-analysis. Clin Kidney J 16: 845–858, 2023 PubMed)| false
• Search Google Scholar
• Export Citation

Ku E, Del Vecchio L, Eckardt KU, Haase VH, Johansen KL, Nangaku M, et al.: Novel anemia therapies in CKD: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int May 24: S0085-2538(23)00379-4, 2023.

• PubMed
Ku E, Del Vecchio L, Eckardt KU, Haase VH, Johansen KL, Nangaku M, et al.: Novel anemia therapies in CKD: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int May 24: S0085-2538(23)00379-4, 2023.)| false
• Search Google Scholar
• Export Citation

Ganz T, Bino A, Salusky IB: Mechanism of action and clinical attributes of Auryxia® (Ferric Citrate). Drugs 79: 957–968, 2019 PubMed

• PubMed
Ganz T, Bino A, Salusky IB: Mechanism of action and clinical attributes of Auryxia^® (Ferric Citrate). Drugs 79: 957–968, 2019 PubMed)| false
• Search Google Scholar
• Export Citation

Lee CT, Lee CC, Wu MJ, Chiu YW, Leu JG, Wu MS, et al.: Long-term safety and efficacy of ferric citrate in phosphate-lowering and iron-repletion effects among patients with on hemodialysis: A multicenter, open-label, Phase IV trial. PLoS One 17: e0264727, 2022 PubMed

• PubMed
Lee CT, Lee CC, Wu MJ, Chiu YW, Leu JG, Wu MS, et al.: Long-term safety and efficacy of ferric citrate in phosphate-lowering and iron-repletion effects among patients with on hemodialysis: A multicenter, open-label, Phase IV trial. PLoS One 17: e0264727, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Yokoyama K, Fukagawa M, Akiba T, Nakayama M, Ito K, Hanaki K, et al.: Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study. Sci Rep 9: 8877, 2019.

• PubMed
Yokoyama K, Fukagawa M, Akiba T, Nakayama M, Ito K, Hanaki K, et al.: Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study. Sci Rep 9: 8877, 2019.)| false
• Search Google Scholar
• Export Citation

Li L, Zheng X, Deng J, Zhou J, Ou J, Hong T: Ferric citrate for the treatment of hyperphosphatemia and anemia in patients with chronic kidney disease: A meta-analysis of randomized clinical trials. Ren Fail 44: 1112–1122, 2022 PubMed

• PubMed
Li L, Zheng X, Deng J, Zhou J, Ou J, Hong T: Ferric citrate for the treatment of hyperphosphatemia and anemia in patients with chronic kidney disease: A meta-analysis of randomized clinical trials. Ren Fail 44: 1112–1122, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Gupta A, Lin V, Guss C, Pratt R, Ikizler TA, Besarab A: Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients. Kidney Int 88: 1187–1194, 2015 PubMed

• PubMed
Gupta A, Lin V, Guss C, Pratt R, Ikizler TA, Besarab A: Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients. Kidney Int 88: 1187–1194, 2015 PubMed)| false
• Search Google Scholar
• Export Citation

Marbury T, van Heuveln F, van der Horst E, Pratt RD: Pharmacokinetics and safety of intravenous ferric pyrophosphate citrate: Equivalence to administration via dialysate. J Clin Pharmacol 62: 681–688, 2022 PubMed

• PubMed
Marbury T, van Heuveln F, van der Horst E, Pratt RD: Pharmacokinetics and safety of intravenous ferric pyrophosphate citrate: Equivalence to administration via dialysate. J Clin Pharmacol 62: 681–688, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Gan L, Xie P, Tan Y, Wei G, Yuan X, Lu Z, et al.: Pharmacokinetics and safety of ferric pyrophosphate citrate in chinese subjects with and without hemodialysis-dependent stage 5 chronic kidney disease. Drugs R D 22: 119–129, 2022 PubMed

• PubMed
Gan L, Xie P, Tan Y, Wei G, Yuan X, Lu Z, et al.: Pharmacokinetics and safety of ferric pyrophosphate citrate in chinese subjects with and without hemodialysis-dependent stage 5 chronic kidney disease. Drugs R D 22: 119–129, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Zhang L, Gan L, Li K, Xie P, Tan Y, Wei G, et al.: Ethnicity evaluation of ferric pyrophosphate citrate among Asian and Non-Asian populations: A population pharmacokinetics analysis. Eur J Clin Pharmacol 78: 1421–1434, 2022 PubMed

• PubMed
Zhang L, Gan L, Li K, Xie P, Tan Y, Wei G, et al.: Ethnicity evaluation of ferric pyrophosphate citrate among Asian and Non-Asian populations: A population pharmacokinetics analysis. Eur J Clin Pharmacol 78: 1421–1434, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Chait Y, Nathanson BH, Germain MJ: Individualized anemia management enhanced by ferric pyrophosphate citrate protocol. Sci Rep 12: 20122, 2022 PubMed

• PubMed
Chait Y, Nathanson BH, Germain MJ: Individualized anemia management enhanced by ferric pyrophosphate citrate protocol. Sci Rep 12: 20122, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Wang S, DellaFera L, Dhanani L, Malone B, Dutka P, Akerman M, et al.: Institutional usage of ferric pyrophosphate citrate (FPC) delivered via dialysate in reducing erythropoiesis stimulating agents (ESAs) and IV iron cost. Hosp Pharm 57: 355–358, 2022 PubMed

• PubMed
Wang S, DellaFera L, Dhanani L, Malone B, Dutka P, Akerman M, et al.: Institutional usage of ferric pyrophosphate citrate (FPC) delivered via dialysate in reducing erythropoiesis stimulating agents (ESAs) and IV iron cost. Hosp Pharm 57: 355–358, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Pergola PE, Fishbane S, Ganz T: Novel oral iron therapies for iron deficiency anemia in chronic kidney disease. Adv Chronic Kidney Dis 26: 272–291, 2019 PubMed

• PubMed
Pergola PE, Fishbane S, Ganz T: Novel oral iron therapies for iron deficiency anemia in chronic kidney disease. Adv Chronic Kidney Dis 26: 272–291, 2019 PubMed)| false
• Search Google Scholar
• Export Citation

Singh K, Sethi Chopra D, Singh D, Singh N: Nano-formulations in treatment of iron deficiency anaemia: An overview. Clin Nutr ESPEN 52: 12–19, 2022 PubMed

• PubMed
Singh K, Sethi Chopra D, Singh D, Singh N: Nano-formulations in treatment of iron deficiency anaemia: An overview. Clin Nutr ESPEN 52: 12–19, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Pisani A, Riccio E, Sabbatini M, Andreucci M, Del Rio A, Visciano B: Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: A randomized trial. Nephrol Dial Transplant 30: 645–652, 2015 PubMed

• PubMed
Pisani A, Riccio E, Sabbatini M, Andreucci M, Del Rio A, Visciano B: Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: A randomized trial. Nephrol Dial Transplant 30: 645–652, 2015 PubMed)| false
• Search Google Scholar
• Export Citation

Riccio E, Sabbatini M, Capuano I, Pellegrino AM, Petruzzelli LA, Pisani A: Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: A cost-minimization analysis. BMC Nephrol 21: 57, 2020 PubMed

• PubMed
Riccio E, Sabbatini M, Capuano I, Pellegrino AM, Petruzzelli LA, Pisani A: Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: A cost-minimization analysis. BMC Nephrol 21: 57, 2020 PubMed)| false
• Search Google Scholar
• Export Citation

Reggiani F, Colombo G, Astori E, Landoni L, Finazzi S, Milzani A, et al.: Preliminary experience on the use of sucrosomial iron in hemodialysis: Focus on safety, hemoglobin maintenance and oxidative stress. Int Urol Nephrol 54: 1145–1153, 2022 PubMed

• PubMed
Reggiani F, Colombo G, Astori E, Landoni L, Finazzi S, Milzani A, et al.: Preliminary experience on the use of sucrosomial iron in hemodialysis: Focus on safety, hemoglobin maintenance and oxidative stress. Int Urol Nephrol 54: 1145–1153, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Renders L, Budde K, Rosenberger C, van Swelm R, Swinkels D, Dellanna F, et al.: First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis. PLoS One 14: e0212023, 2019 PubMed

• PubMed
Renders L, Budde K, Rosenberger C, van Swelm R, Swinkels D, Dellanna F, et al.: First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis. PLoS One 14: e0212023, 2019 PubMed)| false
• Search Google Scholar
• Export Citation

Ganz T: Anemia of inflammation. N Engl J Med 381: 1148–1157, 2019 PubMed

• PubMed
Ganz T: Anemia of inflammation. N Engl J Med 381: 1148–1157, 2019 PubMed)| false
• Search Google Scholar
• Export Citation

van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, et al.: Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman’s disease. J Clin Oncol 28: 3701–3708, 2010 PubMed

• PubMed
van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, et al.: Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman’s disease. J Clin Oncol 28: 3701–3708, 2010 PubMed)| false
• Search Google Scholar
• Export Citation

Pergola PE, Devalaraja M, Fishbane S, Chonchol M, Mathur VS, Smith MT, et al.: Ziltivekimab for treatment of anemia of inflammation in patients on hemodialysis: Results from a phase 1/2 multicenter, randomized, double-blind, placebo-controlled trial. J Am Soc Nephrol 32: 211–222, 2021 PubMed

• PubMed
Pergola PE, Devalaraja M, Fishbane S, Chonchol M, Mathur VS, Smith MT, et al.: Ziltivekimab for treatment of anemia of inflammation in patients on hemodialysis: Results from a phase 1/2 multicenter, randomized, double-blind, placebo-controlled trial. J Am Soc Nephrol 32: 211–222, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Packer M: Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium-glucose cotransporter 2 inhibitors. Eur Heart J Apr 22: ehad235. doi: 10.1093/eurheartj/ehad235, 2023.

• PubMed
Packer M: Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium-glucose cotransporter 2 inhibitors. Eur Heart J Apr 22: ehad235. doi: 10.1093/eurheartj/ehad235, 2023.)| false
• Search Google Scholar
• Export Citation

Fuchs Andersen C, Omar M, Glenthøj A, El Fassi D, Møller HJ, Lindholm Kurtzhals JA, et al.: Effects of empagliflozin on erythropoiesis in heart failure: Data from the Empire HF trial. Eur J Heart Fail 25: 226–234, 2023 PubMed

• PubMed
Fuchs Andersen C, Omar M, Glenthøj A, El Fassi D, Møller HJ, Lindholm Kurtzhals JA, et al.: Effects of empagliflozin on erythropoiesis in heart failure: Data from the Empire HF trial. Eur J Heart Fail 25: 226–234, 2023 PubMed)| false
• Search Google Scholar
• Export Citation

Mazer CD, Hare GMT, Connelly PW, Gilbert RE, Shehata N, Quan A, et al.: Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease. Circulation 141: 704–707, 2020 PubMed

• PubMed
Mazer CD, Hare GMT, Connelly PW, Gilbert RE, Shehata N, Quan A, et al.: Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease. Circulation 141: 704–707, 2020 PubMed)| false
• Search Google Scholar
• Export Citation

Yamada T, Sakaguchi K, Okada Y, Miura H, Otowa-Suematsu N, So A, et al.: Analysis of time-dependent alterations of parameters related to erythrocytes after ipragliflozin initiation. Diabetol Int 12: 197–206, 2020 PubMed

• PubMed
Yamada T, Sakaguchi K, Okada Y, Miura H, Otowa-Suematsu N, So A, et al.: Analysis of time-dependent alterations of parameters related to erythrocytes after ipragliflozin initiation. Diabetol Int 12: 197–206, 2020 PubMed)| false
• Search Google Scholar
• Export Citation

Kobayashi H, Davidoff O, Pujari-Palmer S, Drevin M, Haase VH: EPO synthesis induced by HIF-PHD inhibition is dependent on myofibroblast transdifferentiation and colocalizes with non-injured nephron segments in murine kidney fibrosis. Acta Physiol (Oxf) 235: e13826, 2022 PubMed

• PubMed
Kobayashi H, Davidoff O, Pujari-Palmer S, Drevin M, Haase VH: EPO synthesis induced by HIF-PHD inhibition is dependent on myofibroblast transdifferentiation and colocalizes with non-injured nephron segments in murine kidney fibrosis. Acta Physiol (Oxf) 235: e13826, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Kato S, Ochiai N, Takano H, Io F, Takayama N, Koretsune H, et al.: TP0463518, a novel prolyl hydroxylase inhibitor, specifically induces erythropoietin production in the liver. J Pharmacol Exp Ther 371: 675–683, 2019 PubMed

• PubMed
Kato S, Ochiai N, Takano H, Io F, Takayama N, Koretsune H, et al.: TP0463518, a novel prolyl hydroxylase inhibitor, specifically induces erythropoietin production in the liver. J Pharmacol Exp Ther 371: 675–683, 2019 PubMed)| false
• Search Google Scholar
• Export Citation

Maruyama T, Takashima H, Oguma H, Nakamura Y, Ohno M, Utsunomiya K, et al.: Canagliflozin improves erythropoiesis in diabetes patients with anemia of chronic kidney disease Diabetes Technol Ther 21: 713–720, 2019 PubMed

• PubMed
Maruyama T, Takashima H, Oguma H, Nakamura Y, Ohno M, Utsunomiya K, et al.: Canagliflozin improves erythropoiesis in diabetes patients with anemia of chronic kidney disease Diabetes Technol Ther 21: 713–720, 2019 PubMed)| false
• Search Google Scholar
• Export Citation

Sano M, Goto S: Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation 139: 1985–1987, 2019 PubMed

• PubMed
Sano M, Goto S: Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation 139: 1985–1987, 2019 PubMed)| false
• Search Google Scholar
• Export Citation

Hare GMT, Zhang Y, Chin K, Thai K, Jacobs E, Cazorla-Bak MP, et al.: Impact of sodium glucose linked cotransporter-2 inhibition on renal microvascular oxygen tension in a rodent model of diabetes mellitus. Physiol Rep 9: e14890, 2021 PubMed

• PubMed
Hare GMT, Zhang Y, Chin K, Thai K, Jacobs E, Cazorla-Bak MP, et al.: Impact of sodium glucose linked cotransporter-2 inhibition on renal microvascular oxygen tension in a rodent model of diabetes mellitus. Physiol Rep 9: e14890, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Zanchi A, Burnier M, Muller ME, Ghajarzadeh-Wurzner A, Maillard M, Loncle N, et al.: Acute and chronic effects of SGLT2 inhibitor empagliflozin on renal oxygenation and blood pressure control in nondiabetic normotensive subjects: A randomized, placebo-controlled trial. J Am Heart Assoc 9: e016173, 2020 PubMed

• PubMed
Zanchi A, Burnier M, Muller ME, Ghajarzadeh-Wurzner A, Maillard M, Loncle N, et al.: Acute and chronic effects of SGLT2 inhibitor empagliflozin on renal oxygenation and blood pressure control in nondiabetic normotensive subjects: A randomized, placebo-controlled trial. J Am Heart Assoc 9: e016173, 2020 PubMed)| false
• Search Google Scholar
• Export Citation

Bahena-Lopez JP, Rojas-Vega L, Chávez-Canales M, Bazua-Valenti S, Bautista-Pérez R, Lee JH, et al.: Glucose/fructose delivery to the distal nephron activates the sodium-chloride cotransporter via the calcium-sensing receptor. J Am Soc Nephrol 34: 55–72, 2023 PubMed

• PubMed
Bahena-Lopez JP, Rojas-Vega L, Chávez-Canales M, Bazua-Valenti S, Bautista-Pérez R, Lee JH, et al.: Glucose/fructose delivery to the distal nephron activates the sodium-chloride cotransporter via the calcium-sensing receptor. J Am Soc Nephrol 34: 55–72, 2023 PubMed)| false
• Search Google Scholar
• Export Citation

Packer M: Alleviation of functional iron deficiency by SGLT2 inhibition in patients with type 2 diabetes. Diabetes Obes Metab 25: 1143–1146, 2023 PubMed

• PubMed
Packer M: Alleviation of functional iron deficiency by SGLT2 inhibition in patients with type 2 diabetes. Diabetes Obes Metab 25: 1143–1146, 2023 PubMed)| false
• Search Google Scholar
• Export Citation

Noonan ML, Clinkenbeard EL, Ni P, Swallow EA, Tippen SP, Agoro R, et al.: Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD). Physiol Rep 8: e14434, 2020 PubMed

• PubMed
Noonan ML, Clinkenbeard EL, Ni P, Swallow EA, Tippen SP, Agoro R, et al.: Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD). Physiol Rep 8: e14434, 2020 PubMed)| false
• Search Google Scholar
• Export Citation